BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE
- Product NDC
- 71335-1858
- 11-digit product format
- 713351858
- Labeler code
- 71335
- Product ID
- 71335-1858_9bc52e26-1d52-4d68-894a-d3b300f5f090
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE
- Dosage form
- TABLET
- Route
- SUBLINGUAL
- Labeler
- Bryant Ranch Prepack
- Application
- ANDA209069
- Marketing category
- ANDA
- Marketing start
- 2021-01-22
- Substance
- BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE DIHYDRATE
- Active strength
- 8; 2 mg/1; mg/1
- Pharmacologic classes
- Opioid Antagonist [EPC], Opioid Antagonists [MoA], Partial Opioid Agonist [EPC], Partial Opioid Agonists [MoA]
- DEA schedule
- CIII
- NDC exclude flag
- No
- Listing certified through
- 2026-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | |
| A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A209069-001 | AB |
| A209069-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 03ed91905a0d… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 2680178bc6a6… | |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 2680178bc6a6… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5bbf6a4d5a75… | |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5bbf6a4d5a75… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | d8e5a09893c0… | |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | d8e5a09893c0… | |
| 2024-10-29 15:01 UTC | 2024-10 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | d06236e962d9… | |
| 2024-10-29 15:01 UTC | 2024-10 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | d06236e962d9… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 79d66fd596c7… | |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 79d66fd596c7… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 301d65b070ca… | |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 301d65b070ca… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 1e350fbaab3a… | |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 1e350fbaab3a… | |
| 2024-05-31 18:47 UTC | 2024-05 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 8072bd15b7f6… | |
| 2024-05-31 18:47 UTC | 2024-05 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 8072bd15b7f6… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5c6f7cd8ea54… | |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5c6f7cd8ea54… | |
| 2022-04-08 23:34 UTC | 2022-04 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5d02ea3f76ae… | |
| 2022-04-08 23:34 UTC | 2022-04 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 5d02ea3f76ae… | |
| 2022-04-04 05:41 UTC | 2022-04 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 4b0b4de00fa7… | |
| 2022-04-04 05:41 UTC | 2022-04 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 4b0b4de00fa7… | |
| 2022-03-09 01:35 UTC | 2022-03 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | bb7c543d1eb4… | |
| 2022-03-09 01:35 UTC | 2022-03 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | bb7c543d1eb4… | |
| 2021-12-28 21:50 UTC | 2021-12 | A209069-001 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 2MG BASE;EQ 0.5MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 782e0a99824c… | |
| 2021-12-28 21:50 UTC | 2021-12 | A209069-002 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE | EQ 8MG BASE;EQ 2MG BASE | TABLET / SUBLINGUAL | AB | 2020-07-17 | 782e0a99824c… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A209069-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A209069-002 | AB | 1 | caaa826d4ba7… |
| 2026-02-19 14:30 UTC | 2026-02 | A209069-001 | AB | 1 | 011fe1cb6892… |
| 2026-02-19 14:30 UTC | 2026-02 | A209069-002 | AB | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209069-001 | AB | 1 | 31067a03dcf5… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A209069-002 | AB | 1 | 31067a03dcf5… |
| 2025-08-23 18:47 UTC | 2025-08 | A209069-001 | AB | 1 | 6a471c1ec25d… |
| 2025-08-23 18:47 UTC | 2025-08 | A209069-002 | AB | 1 | 6a471c1ec25d… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A209069-001 | AB | 1 | fd3edfee7708… |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | A209069-002 | AB | 1 | fd3edfee7708… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A209069-001 | AB | 1 | b8a1b40f171c… |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | A209069-002 | AB | 1 | b8a1b40f171c… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A209069-001 | AB | 1 | 03ed91905a0d… |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | A209069-002 | AB | 1 | 03ed91905a0d… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A209069-001 | AB | 1 | 2680178bc6a6… |
| 2024-12-13 21:23 UTC · 2 captures of this ZIP | 2024-12 | A209069-002 | AB | 1 | 2680178bc6a6… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A209069-001 | AB | 1 | 5bbf6a4d5a75… |
| 2024-09-14 05:58 UTC · 2 captures of this ZIP | 2024-09 | A209069-002 | AB | 1 | 5bbf6a4d5a75… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A209069-001 | AB | 1 | d8e5a09893c0… |
| 2024-11-08 22:44 UTC · 3 captures of this ZIP | 2024-11 | A209069-002 | AB | 1 | d8e5a09893c0… |
| 2024-10-29 15:01 UTC | 2024-10 | A209069-001 | AB | 1 | d06236e962d9… |
| 2024-10-29 15:01 UTC | 2024-10 | A209069-002 | AB | 1 | d06236e962d9… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A209069-001 | AB | 1 | 79d66fd596c7… |
| 2024-08-13 05:28 UTC · 3 captures of this ZIP | 2024-08 | A209069-002 | AB | 1 | 79d66fd596c7… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A209069-001 | AB | 1 | 301d65b070ca… |
| 2024-07-13 05:37 UTC · 2 captures of this ZIP | 2024-07 | A209069-002 | AB | 1 | 301d65b070ca… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A209069-001 | AB | 1 | 1e350fbaab3a… |
| 2024-06-18 03:08 UTC · 5 captures of this ZIP | 2024-06 | A209069-002 | AB | 1 | 1e350fbaab3a… |
| 2024-05-31 18:47 UTC | 2024-05 | A209069-001 | AB | 1 | 8072bd15b7f6… |
| 2024-05-31 18:47 UTC | 2024-05 | A209069-002 | AB | 1 | 8072bd15b7f6… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A209069-001 | AB | 1 | 5c6f7cd8ea54… |
| 2022-06-29 02:47 UTC · 2 captures of this ZIP | 2022-06 | A209069-002 | AB | 1 | 5c6f7cd8ea54… |
| 2022-04-08 23:34 UTC | 2022-04 | A209069-001 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-08 23:34 UTC | 2022-04 | A209069-002 | AB | 1 | 5d02ea3f76ae… |
| 2022-04-04 05:41 UTC | 2022-04 | A209069-001 | AB | 1 | 4b0b4de00fa7… |
| 2022-04-04 05:41 UTC | 2022-04 | A209069-002 | AB | 1 | 4b0b4de00fa7… |
| 2022-03-09 01:35 UTC | 2022-03 | A209069-001 | AB | 1 | bb7c543d1eb4… |
| 2022-03-09 01:35 UTC | 2022-03 | A209069-002 | AB | 1 | bb7c543d1eb4… |
| 2021-12-28 21:50 UTC | 2021-12 | A209069-001 | AB | 1 | 782e0a99824c… |
| 2021-12-28 21:50 UTC | 2021-12 | A209069-002 | AB | 1 | 782e0a99824c… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE
- Listing expiration
- 2026-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| BUPRENORPHINE HYDROCHLORIDE | 8 mg/1 |
| NALOXONE HYDROCHLORIDE DIHYDRATE | 2 mg/1 |
Harmonized UNII identifiers#
| Identifier | FDA.report destination |
|---|---|
| 56W8MW3EN1 | Internal UNII lookup |
| 5Q187997EE | Internal UNII lookup |
Harmonized RxCUI identifiers#
| Identifier | FDA.report destination |
|---|---|
| 351267 | Internal RxNorm lookup |
Harmonized SPL set identifiers#
| Identifier | FDA.report destination |
|---|---|
| 53457b0d-3462-489e-8cf5-7cdc2ecffb48 | Available on FDA.report |
DailyMed Product Concepts#
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 71335-1858-0 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 42 in 1 BOTTLE, PLASTIC | TABLET | 42 | 104 | |
| 71335-1858-1 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 30 in 1 BOTTLE, PLASTIC | TABLET | 30 | 104 | |
| 71335-1858-2 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 60 in 1 BOTTLE, PLASTIC | TABLET | 60 | 104 | |
| 71335-1858-3 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 90 in 1 BOTTLE, PLASTIC | TABLET | 90 | 104 | |
| 71335-1858-4 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 120 in 1 BOTTLE, PLASTIC | TABLET | 120 | 104 | |
| 71335-1858-5 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 14 in 1 BOTTLE, PLASTIC | TABLET | 14 | 104 | |
| 71335-1858-6 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 28 in 1 BOTTLE, PLASTIC | TABLET | 28 | 104 | |
| 71335-1858-7 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 6 in 1 BOTTLE, PLASTIC | TABLET | 6 | 104 | |
| 71335-1858-8 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 10 in 1 BOTTLE, PLASTIC | TABLET | 10 | 104 | |
| 71335-1858-9 | BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | 21 in 1 BOTTLE, PLASTIC | TABLET | 21 | 104 |
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 71335-1858-1 | EA - Each | 71335-1858 | 520ed9bc-884f-4717-afba-5b3ee81c7fd9 | 1 | 2021-11-09 |
| 71335-1858-2 | EA - Each | 71335-1858 | ae1d94bb-2def-4fb3-a282-e7d8e19fa4a3 | 1 | 2021-11-09 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 71335-1858 | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE TABLET [BRYANT RANCH PREPACK] | 104 | Current NDC, Legacy NDC, 10 package rows | 20231117_53457b0d-3462-489e-8cf5-7cdc2ecffb48.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Clinical Solutions Wholesale, LLC | 8f2b94dc-f42f-45d5-8274-9e748ec20ef0 | 2026-03-05 | Warnings, Adverse reactions | 209069 ANDA209069 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Redpharm Drug | 44f2e26f-4586-5204-e063-6394a90a47d5 | 2026-01-23 | Warnings, Adverse reactions | 209069 ANDA209069 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Bryant Ranch Prepack | 53457b0d-3462-489e-8cf5-7cdc2ecffb48 | 2023-11-16 | Warnings, Adverse reactions | 209069 ANDA209069 71335-1858 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Accord Healthcare, Inc | 35d29e9b-9950-452a-a795-5a7514f0edfd | 2023-05-03 | Warnings, Adverse reactions | 209069 ANDA209069 |
| BUPRENORPHINE HYDROCHLORIDE and NALOXONE HYDROCHLORIDE DIHYDRATE | BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE DIHYDRATE | Asclemed USA, Inc. | 597cbc69-84b1-4255-bed9-53d0c6dc2134 | 2023-01-27 | Warnings, Adverse reactions | 209069 ANDA209069 |
DailyMed RxNorm Mappings#
| RxCUI | RxNorm string | TTY | DailyMed | SPL version |
|---|---|---|---|---|
| 351267 | buprenorphine HCl 8 MG / naloxone HCl 2 MG Sublingual Tablet | PSN | 53457b0d-3462-489e-8cf5-7cdc2ecffb48 | 104 |
| 351267 | buprenorphine 8 MG / naloxone 2 MG Sublingual Tablet | SCD | 53457b0d-3462-489e-8cf5-7cdc2ecffb48 | 104 |
| 351267 | buprenorphine 8 MG (as buprenorphine HCl) / naloxone 2 MG (as naloxone HCl) Sublingual Tablet | SY | 53457b0d-3462-489e-8cf5-7cdc2ecffb48 | 104 |
Packages#
| Package NDC | 11-digit format | Description | Units | Marketing start | Marketing end | Sample | Exclude flag | Status |
|---|---|---|---|---|---|---|---|---|
| 71335-1858-0 | 71335185800 | 42 TABLET in 1 BOTTLE, PLASTIC (71335-1858-0) | 42 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-1 | 71335185801 | 30 TABLET in 1 BOTTLE, PLASTIC (71335-1858-1) | 30 tablet | 2021-05-07 | 0000-00-00 | No | No | Current |
| 71335-1858-2 | 71335185802 | 60 TABLET in 1 BOTTLE, PLASTIC (71335-1858-2) | 60 tablet | 2021-06-08 | 0000-00-00 | No | No | Current |
| 71335-1858-3 | 71335185803 | 90 TABLET in 1 BOTTLE, PLASTIC (71335-1858-3) | 90 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-4 | 71335185804 | 120 TABLET in 1 BOTTLE, PLASTIC (71335-1858-4) | 120 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-5 | 71335185805 | 14 TABLET in 1 BOTTLE, PLASTIC (71335-1858-5) | 14 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-6 | 71335185806 | 28 TABLET in 1 BOTTLE, PLASTIC (71335-1858-6) | 28 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-7 | 71335185807 | 6 TABLET in 1 BOTTLE, PLASTIC (71335-1858-7) | 6 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-8 | 71335185808 | 10 TABLET in 1 BOTTLE, PLASTIC (71335-1858-8) | 10 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |
| 71335-1858-9 | 71335185809 | 21 TABLET in 1 BOTTLE, PLASTIC (71335-1858-9) | 21 tablet | 2022-02-14 | 0000-00-00 | No | No | Current |